Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage

A method for delivering sodium pyruvate and other drugs through biofilms and mucus barriers to stimulate and increase the synthesis of nasal nitric oxide, that will reduce viral and bacterial replication, duration, spread and counts to reduce the severity of infections, to increase lung and sinus functions, reduce coughing, sneezing, inflammatory cytokines and toxins that effect the Vagus nerve, caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, long COVID, interstitial lung disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, rhinitis medicamentosa also known as rebound rhinitis, allergic rhinitis, congestion, rebound effects of oxymetazoline, seasonal allergies, sinusitis, with migraines, Alzheimer's, Parkinsons and pulmonary hypertension which comprises:

• contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents:
• a) sodium pyruvate;
• b) sodium chloride;
• c) benzalkonium chloride;
• d) an alcohol selected from:
• ethanol, isopropanol, methyl alcohol or phenylethyl alcohol;
• and,
• e) an aqueous carrier;
• wherein said composition contains the following amounts of said constituents:
• sodium pyruvate ranges from about 0.01% to 1%, sodium chloride ranges from 0.45% to 0.93%;
• benzalkonium chloride ranges from 0.01% to about 0.2% and alcohol ranges from 0.01% to about 0.2%, balance is said aqueous carrier, all percentages by weight.

A method for delivering sodium pyruvate and other drugs through biofilms and mucus barriers to stimulate and increase the synthesis of nasal nitric oxide, that will reduce viral and bacterial replication, duration, spread and counts to reduce the severity of infections, to increase lung and sinus functions, reduce coughing, sneezing, inflammatory cytokines and toxins that effect the Vagus nerve, caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, long COVID, interstitial lung disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, rhinitis medicamentosa also known as rebound rhinitis, allergic rhinitis, congestion, rebound effects of oxymetazoline, seasonal allergies, sinusitis, with migraines, Alzheimer's, Parkinsons and pulmonary hypertension which comprises:

• contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents:
• f) sodium pyruvate;
• g) sodium chloride;
• h) benzalkonium chloride;
• i) an alcohol selected from:
• ethanol, isopropanol, methyl alcohol or phenylethyl alcohol;
• and,
• j) an aqueous carrier;
• wherein said composition contains the following amounts of said constituents:
• sodium pyruvate ranges from about 0.01% to 1%, sodium chloride ranges from 0.45% to 0.93%;
• benzalkonium chloride ranges from 0.01% to about 0.2% and alcohol ranges from 0.01% to about 0.2%, balance is said aqueous carrier, all percentages by weight;
• and,
• wherein a therapeutic agent is administered relative to contacting said mammalian cells with said composition, and said therapeutic agent is administered at a time selected from the group consisting of:
• prior to, simultaneously with, and after, contacting said mammalian cells with said composition.